I am so tired of AZN doing nothing all day. Can you move??? I have been reading (http://Achieverspot.tech) for a month now and the stocks there actually go!
C
Too many scams out here but I can’t be scared of making money. If its worth the Risk I’m in 💯. I started investing using Jeff Rogers Platform Last Year , he shared his commercial techniques and helped me achieve my goals and now the profit rate is exponential. Contact On. 🆃🅴🅻🅴🅶🆁🅼: (@Jeff_Rogers1) Look Up To Him On Wh@+$@pp +1 (317) 953‑3794
Bullish
D
By Jaime Llinares Taboada
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.
The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
People are taking profit from AZN and moving it to other stocks that has dropped a lot more. AZN was a safety play in the past year since it hasn’t dropped much at all…. Remember in a recession, all stocks go down eventually as it’s needed to reach a bottom
Bearish
T
Hey Froehling what did you say
j
Stockmarkets are forward looking. Flu season peaks around 6 months from now.
Bullish
I
Good news from ASCO on impact of Inhertu on late stage breast cancer.
D
1.85% of institutions would consider $AZN a core holding, constituting over 8% of their portfolio
Bullish
D
Looks like people are taking notice.
C
Anybody looking at AZN for the first time as potential IRA investment only need look at the 5 yeat chart and ask themselves whether it has the shape they would want in a retirement account.
C
Swedish stocks propose a dividend in the call tp AGM, the AGM votes to ratify the dividend, then the ec div date is the next day ( used to be 2 days after AGM). So I am guessing AZN will announce the 2nd half yearly dividend and an august ex-div date and a sept pay date at the next ER in july, I expect 49c+/- 1c
s
Another one of my stocks that is beating the market. Got in via the ALXN deal, which ours my cost basis somewhere in the mid 50’s!
Just think instead of owning great stocks like AZN and VRTX you could own a retailer like #FIVE and be down 40%! But the market needs failures too!
1
Plieth
Another 1st-line urothelial cancer trial draws a blank for IO: $BMY Opdivo + Yervoy just failed in CM-901, after $AZN Imfinzi + treme failed in Danube, and $MRK Keytruda failed in KN-361
C
Yahoo censoring again. Not acceptable. Can't wait for Elon to fix all that.
C
I am expecting the market to roar back from here as stocks like AZN are an INFLATION-INDEXED asset.
M
Excellent earnings . Market conditions in correct or we see new 52 week highs
A
I bought this in 2019 at 6300 and just left it for the children as savings. It’s grown steady and I’m hoping the children don’t want the money any time soon as I see this growing a lot more
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.
The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.
Just think instead of owning great stocks like AZN and VRTX you could own a retailer like #FIVE and be down 40%! But the market needs failures too!
Another 1st-line urothelial cancer trial draws a blank for IO: $BMY Opdivo + Yervoy just failed in CM-901, after $AZN Imfinzi + treme failed in Danube, and $MRK Keytruda failed in KN-361